TAST 2011 â€” Thrombolysis and Acute Stroke Treatment in 2011: Preparing for the Next Decade (TAST2011)
|Event Date/Time: Dec 01, 2011||End Date/Time: Dec 03, 2011|
The majority of strokes are due to thrombotic or thromboembolic blockage of an artery supplying the brain. Prompt treatment with thrombolytic agents can restore blood flow, limiting brain damage and improving recovery prognosis after ischemic stroke. Use of thrombolytic agents, including recombinant tissue-type plasminogen activator (rt-PA), over the past thirty years has enhanced patient outcomes, but has also highlighted many other aspects of the medical setting that impact treatment success. This symposium will explore these facets of acute intervention and a number of unaddressed issues related to the medical setting of stroke that provide opportunities for improving treatment. Following on ten previous international symposia on the theme of thrombolytic treatment in acute ischemic stroke (i.e. TTAST, TAST), the New York Academy of Sciences is proud to undertake the 11th meeting in this series (TAST 2011) to focus on these issues.
The program will feature keynote and plenary lectures, short oral and poster presentations selected from abstract submissions, a mini-symposium, and a hands-on workshop on Advanced Multi-modal Neuroimaging and Ultrasound Techniques. There will be multiple opportunities for audience and panel discussion. Speakers will be asked to respond to sets of questions during their presentations to foster the generation of data-driven, multidisciplinary ideas, to explore ischemic stroke as a systemic disease related to other disease entities (hypertension, diabetes, and disorders of aging), and to better address the evolution of ischemic brain injury.
Highlighted topics include: (i) the neurovascular unit and its injury; (ii) the safety and efficacy of thrombolytic agents currently used or being developed for acute stroke treatment; (iii) new views of the penumbra; (iv) time window considerations and optimized delivery conditions; (v) stabilization of brain tissue for patient recovery; (vi) enhancing the safety of plasminogen activators; (vii) factors that influence risk and benefit; and (viii) alternative approaches in stroke treatment.